On November 18, Gelonghui reported that Tai'enkang (301263.SZ) announced in a recent investor relations activity that the company will promote nationwide after obtaining domestic registration approval for the Weizhengchang tablets, further expanding the market share of this variety, and aims to develop it into a well-known product in the gastrointestinal field worth over 1 billion yuan in the next 3 to 5 years.
泰恩康(301263.SZ)：在未来3至5年内争取将和胃整肠丸打造为超10亿元的肠胃领域知名产品
Taien Health (301263.SZ): Strive to make He Wei Zheng Chang Wan a well-known product in the digestive tract field with sales exceeding 1 billion yuan in the next 3 to 5 years.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated